These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12840823)

  • 21. The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
    Bergeron RJ; Wiegand J; Ratliff-Thompson K; Weimar WR
    Ann N Y Acad Sci; 1998 Jun; 850():202-16. PubMed ID: 9668541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, theoretical and structural analyses, and enantiopharmacology of 3-carboxy homologs of AMPA.
    Brehm L; Greenwood JR; Sløk FA; Holm MM; Nielsen B; Geneser U; Stensbøl TB; Bräuner-Osborne H; Begtrup M; Egebjerg J; Krogsgaard-Larsen P
    Chirality; 2004 Aug; 16(7):452-66. PubMed ID: 15236343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
    Bergeron RJ; Wiegand J; McManis JS; Bharti N; Singh S
    J Med Chem; 2008 Jul; 51(13):3913-23. PubMed ID: 18533709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scaffold Based Search on the Desferithiocin Archetype.
    Shyam M; Dev A; Sinha BN; Jayaprakash V
    Mini Rev Med Chem; 2019; 19(19):1564-1576. PubMed ID: 30827237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desferrithiocin: a search for clinically effective iron chelators.
    Bergeron RJ; Wiegand J; McManis JS; Bharti N
    J Med Chem; 2014 Nov; 57(22):9259-91. PubMed ID: 25207964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity.
    Opletalová V; Kalinowski DS; Vejsová M; Kunes J; Pour M; Jampílek J; Buchta V; Richardson DR
    Chem Res Toxicol; 2008 Sep; 21(9):1878-89. PubMed ID: 18698850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure at high resolution of ferric-pyochelin and its membrane receptor FptA from Pseudomonas aeruginosa.
    Cobessi D; Celia H; Pattus F
    J Mol Biol; 2005 Sep; 352(4):893-904. PubMed ID: 16139844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolution of iron chelators for the treatment of iron overload disease and cancer.
    Kalinowski DS; Richardson DR
    Pharmacol Rev; 2005 Dec; 57(4):547-83. PubMed ID: 16382108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
    Donovan JM; Plone M; Dagher R; Bree M; Marquis J
    Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue.
    Rivara S; Diamantini G; Di Giacomo B; Lamba D; Gatti G; Lucini V; Pannacci M; Mor M; Spadoni G; Tarzia G
    Bioorg Med Chem; 2006 May; 14(10):3383-91. PubMed ID: 16431121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
    Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2008 Jan; 51(2):331-44. PubMed ID: 18159922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
    Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racemic atropisomeric N,N-chelate ligands for recognizing chiral carboxylates via Zn(II) coordination: structure, fluorescence, and circular dichroism.
    McCormick TM; Wang S
    Inorg Chem; 2008 Nov; 47(21):10017-24. PubMed ID: 18831581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolically programmed iron chelators.
    Bergeron RJ; Bharti N; McManis JS; Wiegand J
    Bioorg Med Chem; 2015 Sep; 23(17):5954-71. PubMed ID: 26231739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
    Bergeron RJ; Streiff RR; Creary EA; Daniels RD; King W; Luchetta G; Wiegand J; Moerker T; Peter HH
    Blood; 1993 Apr; 81(8):2166-73. PubMed ID: 8471775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
    Bergeron RJ; Wiegand J; McManis JS; Vinson JR; Yao H; Bharti N; Rocca JR
    J Med Chem; 2006 May; 49(9):2772-83. PubMed ID: 16640338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and characterization of new beta-diketo derivatives with iron chelating ability.
    Benassi R; Ferrari E; Grandi R; Lazzari S; Saladini M
    J Inorg Biochem; 2007 Feb; 101(2):203-13. PubMed ID: 17097145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK; Kalinowski DS; Richardson DR
    Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly enantioselective synthesis, crystal structure, and circular dichroism spectroscopy of (R)-bambuterol hydrochloride.
    Cao G; Hu AX; Zou KS; Xu L; Chen JL; Tan W
    Chirality; 2008 Jul; 20(7):856-62. PubMed ID: 18381733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.